Medigrowth backs National Pain Week as Gold Sponsor

Medigrowth will serve as Gold Sponsor of National Pain Week 2026, joining Chronic Pain Australia’s campaign for the 5.4 million Australians living with chronic pain. The partnership adds a video series, a longer-form interview and sponsorship of the 2026 National Pain Report as medicinal cannabis use continues to rise among pain patients.

Why it matters: - National Pain Week is a major awareness campaign for Australians living with chronic pain. - The partnership is aimed at reducing stigma and improving access to reliable, evidence-based information. - Chronic Pain Australia is using the campaign to push for chronic pain to be recognized as a National Health Priority Area. - Medigrowth is positioning cannabinoid therapeutics as a more visible part of the pain-care conversation.

What happened: - Medigrowth was announced as Gold Sponsor of National Pain Week 2026. - National Pain Week runs from 26 to 31 July 2026. - The campaign is led by Chronic Pain Australia. - Medigrowth will also be Gold Sponsor of the 2026 National Pain Report. - The sponsorship aligns Medigrowth with Chronic Pain Australia’s effort to support the 5.4 million Australians living with chronic pain.

The details: - Medigrowth produced a five-part video series focused on common questions about medicinal cannabis. - The videos are titled: “What’s the Deal with Medicinal Cannabis?”, “What Does Medicinal Cannabis Feel Like?”, “Will People Know I’ve Tried Medicinal Cannabis?”, “Will Medicinal Cannabis Work for Me?” and “Will Medicinal Cannabis Get Me High?” - Medigrowth also created a longer interview titled “Pain Lives in Women’s Health.” - The interview features Medigrowth’s Melanie Wentzel and Chronic Pain Australia General Manager Kellie Jade Ellis. - The discussion covers healthcare leadership and Ellis’s endometriosis experience. - Medigrowth’s broader focus includes person-centred, evidence-based care for people living with chronic and complex pain conditions. - Chronic Pain Australia says the National Pain Survey is the longest-running survey documenting the experiences of Australians living with chronic pain. - The past three National Pain Reports show a growing role for medicinal cannabis in pain management. - In 2025, 31% of respondents had accessed medicinal cannabis for pain management, up from 28% in 2024. - Another 27.5% said they would like to or intend to try medicinal cannabis. - That means more than half of respondents either use or are interested in medicinal cannabis as a treatment option. - The barriers people report, including cost and driving restrictions, have each eased slightly year over year. - Medigrowth Australia is an Australian biotechnology, digital health and clinical research organization focused on cannabinoid therapeutics and evidence-based healthcare. - Medigrowth conducts clinical research, develops cannabinoid therapeutics for the Australian market and supports patient care through its digital health platform, Azure Health. - Medigrowth says its work spans women’s health, pediatric populations and chronic pain. - The company cites a randomized, double-blind, placebo-controlled clinical trial with Deakin University and Swinburne University on CBD in children and families living with autism. - Medigrowth also cites the EMPOWER Project, a prospective, HREC-approved real-world evidence study following up to 5,000 patients over four years. - Chronic Pain Australia is a non-profit, non-government organization and the national voice for the 3.6 million Australians living with chronic pain. - Chronic Pain Australia was founded in 2001. - The organization runs National Pain Week, the National Pain Survey, PainLink support services and a national network of peer-led Pain Support Groups. - Medigrowth provides more information at Medigrowth’s website. - Chronic Pain Australia provides more information at Chronic Pain Australia’s website.

Between the lines: - The sponsorship gives Medigrowth a platform to normalize medicinal cannabis conversations in a chronic pain audience that is already showing interest in the treatment. - The survey data suggests demand is outpacing comfort, with cost and driving rules still shaping access decisions. - The partnership also gives Chronic Pain Australia a corporate ally with clinical and digital health credentials as it expands campaign reach.

What’s next: - National Pain Week will run across 26-31 July 2026. - Medigrowth will use the campaign period to circulate its video series and interview content. - Chronic Pain Australia will continue using the National Pain Survey and National Pain Report to track pain experiences and treatment trends. - The organizations are likely to keep framing chronic pain care around access, education and stigma reduction.

The bottom line: - Medigrowth is betting that public education and patient-centered messaging can move medicinal cannabis from a misunderstood option to a mainstream pain-management conversation.